Systematic review of prediction models in relapsing remitting multiple sclerosis
- PMID: 32453803
- PMCID: PMC7250448
- DOI: 10.1371/journal.pone.0233575
Systematic review of prediction models in relapsing remitting multiple sclerosis
Abstract
The natural history of relapsing remitting multiple sclerosis (RRMS) is variable and prediction of individual prognosis challenging. The inability to reliably predict prognosis at diagnosis has important implications for informed decision making especially in relation to disease modifying therapies. We conducted a systematic review in order to collate, describe and assess the methodological quality of published prediction models in RRMS. We searched Medline, Embase and Web of Science. Two reviewers independently screened abstracts and full text for eligibility and assessed risk of bias. Studies reporting development or validation of prediction models for RRMS in adults were included. Data collection was guided by the checklist for critical appraisal and data extraction for systematic reviews (CHARMS) and applicability and methodological quality assessment by the prediction model risk of bias assessment tool (PROBAST). 30 studies were included in the review. Applicability was assessed as high risk of concern in 27 studies. Risk of bias was assessed as high for all studies. The single most frequently included predictor was baseline EDSS (n = 11). T2 Lesion volume or number and brain atrophy were each retained in seven studies. Five studies included external validation and none included impact analysis. Although a number of prediction models for RRMS have been reported, most are at high risk of bias and lack external validation and impact analysis, restricting their application to routine clinical practice.
Conflict of interest statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: NM has received hospitality for educational events from Biogen, Novartis, Genzyme, Merck and Roche over the past 5 years. NM has received honoraria for talks or advisory boards from Biogen, Novartis, Genzyme, Merck and Roche over the same time period. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
References
-
- Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989;112;(6): 1419–28. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
